Hyaluronic Acid for the Treatment of Damaged Nipples in Breastfeeding Women

The Effectiveness of Hyaluronic Acid for the Treatment of Damaged Nipples in Breastfeeding Women: a Double-blind Randomised, Controlled Trial

Previous studies have shown that application of hyaluronic acid preparations to wounds of the skin and mucosa have a beneficial effect.

There is a lack of studies showing the effect of applying hyaluronic acid preparations to treat damaged nipple skin in breastfeeding mothers.

This study aims to determine the effect of applying a hyaluronic acid preparation to damaged nipple skin in breastfeeding women.

Study Overview

• Status: Recruiting
• Conditions: Healing Wound; Breastfeeding; Cracked Nipple
• Intervention / Treatment: Drug: Treatment of damaged nipple skin: Preparation with hyaluronic acid; Drug: Treatment of damaged nipple skin: Neutral preparation without hyaluronic acid

Detailed Description

A randomised, controlled, parallel, double-blinded clinical trial will be performed in the Breastfeeding Support Unit of the Health Centre 'Dom zdravlja' in Osijek-Baranja County, Croatia, in 2022.

A randomised controlled study design has been chosen for this trial to compare two ways of treating damaged nipples in breastfeeding women. Participants will be randomly divided into two groups. The randomisation procedure will ensure the reliability of the results. Participants are breastfeeding mothers, with damaged nipples, and their newborn babies. Eligible mothers will be directed to the Breastfeeding Support Unit by the Health Centre's Health Visitors during regular home visits. Participants will be included in the study only if both mother and child meet the inclusion criteria.

Participants will be divided into two groups by simple randomisation: a group receiving a hyaluronic acid preparation and a control group receiving a placebo preparation. Allocation will be performed using a computer-generated list of random numbers. The allocator will know which participant receives which preparation, whereas the main researcher and the participants will not know which preparation is used by any participants. All pregnancy and birth data will be collected from the medical documentation of the mother and the child.

The preparation containing hyaluronic acid and the neutral agent will be prepared in the Galenska laboratory, Ljekarna Srce, Osijek-Baranja County. The hyaluronic acid preparation will contain white vaseline and 0.2% sodium hyaluronate in a 30 g container. The preparation will be applied for five days, locally on the nipple skin area after every second breastfeeding session and at least four times in 24 hours, alternating it with breast milk. The hyaluronic acid preparation will be distributed in the same packaging as the neutral agent used by the control group. The control group participants will apply the neutral agent containing only white vaseline for five days after every second breastfeeding session and at least four times in 24 hours, alternating it with breast milk. All mothers will be advised to wash the nipple skin with water before the next breastfeed.

The participants will be examined four times during their first postpartum month in the Breastfeeding Support Unit of the Health Centre 'Dom zdravlja'. The first check-up will occur 72 to 120 hours postpartum when the participants will be introduced to the study, provide consent for participation in the study, and, according to the allocator's instructions, will receive the preparation to treat the damaged nipple skin. Then, the researcher will advise the participants on how to position their babies during breastfeeding and correct possible irregularities.

The next check-up will occur at the Breastfeeding Support Unit on the seventh postpartum day when the condition of the damaged skin will be evaluated. The other check-ups will occur on the 10th and 30th postpartum days in the Breastfeeding Support Unit. During every checkup, the condition of the damaged nipple skin will be evaluated, participants will estimate the soreness on a visual analogue scale, and the mother's satisfaction with the treatment method will be assessed. During every visit, the baby's diet will be checked and noted, and possible side effects in the mother and child will be recorded.

Nipple healing will be measured using the Nipple Trauma Score (NTS), and the measurement will be done by the lead researcher. During the nipple skin checkup, the following NTS interpretation will be applied: 0) no macroscopically visible skin changes; 1) erythema or edema or combination of both; 2) superficial damage with or without scab formation of less than 25% of the nipple surface; 3) superficial damage with or without scab formation of more than 25% of the nipple surface; 4) partial-thickness wound with or without scab formation of less than 25% of the nipple surface; 5) partial-thickness wound with or without scab formation of more than 25% of the nipple surface.

Nipple pain will be estimated using an adapted visual analogue scale (VAS). The pain scale is marked by numbers 0 to 10, where 0 means no pain, and 10 is the highest pain imaginable. The mother will decide on the VAS scale, which measure best fits her pain: 0) no pain, feeling that the child is moving my breast; 1-2) minimal discomfort and pain; 3-5) moderate pain; 6-8) severe pain; 9-10) the severest pain I can imagine.

The mother's satisfaction with the applied preparation will be measured using a Likert scale. The mother will choose one of the given answers: 1- Very dissatisfied; 2 - Dissatisfied; 3 - Neutral/ don't have an opinion; 4 - Satisfied; and 5 - Very satisfied.

During Breastfeeding Support Unit visits, mothers will be asked whether they have noticed any side effects in either themselves or their child. In addition, infant feeding will be monitored, specifically if breastfeeding is exclusive during the first month. World Health Organisation (WHO) definitions will be used, according to which exclusive breastfeeding is defined as feeding the child with breast milk only, without any other fluids or food, besides minerals and vitamins.

The researcher aims to find the middle effect in the difference of numerical variables between the participants in the two independent groups, with a 0.05 level of significance and 0.08 statistical power; hence, the minimal sample needed is 64 participants per group or 128 participants in total. Assuming a 20% loss of participation within the study group, the expected sample is 160 participants to detect a statistically significant difference.

This study will use rigorous scientific procedures to investigate whether hyaluronic acid is more efficient in treating nipple skin damage in breastfeeding mothers than a neutral agent. If the intervention proves to be effective, i.e. if there is faster healing of the damaged nipple skin and a reduction in pain, it may be a potential way of easing breastfeeding difficulties of mothers at the beginning of the breastfeeding period, which might lead to a more significant percentage of breastfed children which will benefit the whole of society.

• Study Type: Interventional
• Enrollment (Anticipated): 160
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Maja Štimac, MD; Mr.sc.; Phone Number: +385 98 799 188; Email: maja@stimac.org

Study Locations

• Croatia
  • Osijek, Croatia, 31000
    • Recruiting
    • Savjetovalište za dojenje, Dom zdravlja Osječko-baranjske županije
    • Contact: Dragica Pavlović, mag.med.techn.; Phone Number: +385 99 815 47 60; Email: dragica.pavlovic@dzobz.hr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• for mothers: a breastfeeding mother, living or residing in Osijek, with nipple skin damage (NTS 1, 2, 3, 4, or 5).
• for babies: newborns from a singleton pregnancy, of gestational age from 37 to 42 weeks, with a birth weight of 2,500 to 4,500 grams.

Exclusion Criteria:

• for mothers: mothers who do not breastfeed, mothers not living or residing in Osijek, mothers without nipple skin damage and mothers using other preparations for healing sore nipples (shells, pads).
• for children: visible anomalies in the newborn which may affect the breastfeeding process, newborns that required admission to the neonatal unit

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Preparation with hyaluronic acid; Treatment of damaged nipple skin: Preparation with hyaluronic acid. The hyaluronic acid preparation will contain white vaseline and 0.2% sodium hyaluronate in a 30 g container.	Drug: Treatment of damaged nipple skin: Preparation with hyaluronic acid; The active preparation will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
Experimental: Neutral Preparation without hyaluronic acid; Treatment of damaged nipple skin: Neutral preparation without hyaluronic acid. The neutral preparation will contain white vaseline only, in a 30 g container, and wiil have the same appearance and fragrance as the active preparation.	Drug: Treatment of damaged nipple skin: Neutral preparation without hyaluronic acid; The neutral preparation, containing only white vaseline, will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Healing of damaged nipples	Nipple healing will be measured using the Nipple Trauma Score (NTS). Measurements will be performed by the lead researcher using the following scale: 0) no macroscopically visible skin changes; 1) erythema or edema or combination of both; 2) superficial damage with or without scab formation of less than 25% of the nipple surface; 3) superficial damage with or without scab formation of more than 25% of the nipple surface; 4) partial-thickness wound with or without scab formation of less than 25% of the nipple surface; 5) partial-thickness wound with or without scab formation of more than 25% of the nipple surface.	30 days
Level of nipple pain	Nipple pain will be estimated using an adapted VAS.The pain scale is marked by numbers 0 to 10, where 0 means no pain, and 10 is the highest pain imaginable. The mother will decide on the VAS scale, which measure best fits her pain: 0) no pain, feeling that the child is moving my breast; 1-2) minimal discomfort and pain; 3-5) moderate pain; 6-8) severe pain; 9-10) the severest pain I can imagine.	30 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mother's satisfaction with allocated treatment	The mother's satisfaction with the applied preparation will be measured using a Likert scale. The mother will be able to choose one of the following options: 1- Very dissatisfied; 2 - Dissatisfied; 3 - Neutral/ don't have an opinion; 4 - Satisfied; and 5 - Very satisfied.	30 days
Exclusive breastfeeding rates at days 3, 7, 10, and 30 postpartum.	During the Breastfeeding Support Unit visits, mothers wiil be asked by the lead researcher how their newborn was fed in the previous 24h, and since the last visit. WHO breastfeeding definitions wiil be used, according to which exclusive breastfeeding is defined as receiving only human milk, without any other fluids or food, apart from minerals and vitamins.	30 days
Side effects in mother and child	During Breastfeeding Support Unit visits, mothers will be asked whether they have noticed any side effects on themselves or on their infants.	30 days

Collaborators and Investigators

• Sponsor: Specijalisticka Pedijatrijska Ordinacija prim.mr.sc. Maja Stimac, Specijalist Pedijatrije Sspecijalnosti Neonatologije
• Investigators: Principal Investigator: Maja Štimac, MD; Mr.sc., Specijalistička pedijatrijska ordinacija prim.mr.sc.Maja Štimac

Publications and helpful links

General Publications

• Tait P. Nipple pain in breastfeeding women: causes, treatment, and prevention strategies. J Midwifery Womens Health. 2000 May-Jun;45(3):212-5. doi: 10.1016/s1526-9523(00)00011-8.
• Abou-Dakn M, Fluhr JW, Gensch M, Wockel A. Positive effect of HPA lanolin versus expressed breastmilk on painful and damaged nipples during lactation. Skin Pharmacol Physiol. 2011;24(1):27-35. doi: 10.1159/000318228. Epub 2010 Aug 18.
• Shaharudin A, Aziz Z. Effectiveness of hyaluronic acid and its derivatives on chronic wounds: a systematic review. J Wound Care. 2016 Oct 2;25(10):585-592. doi: 10.12968/jowc.2016.25.10.585.
• Torretta S, Marchisio P, Rinaldi V, Carioli D, Nazzari E, Pignataro L. Endoscopic and clinical benefits of hyaluronic acid in children with chronic adenoiditis and middle ear disease. Eur Arch Otorhinolaryngol. 2017 Mar;274(3):1423-1429. doi: 10.1007/s00405-016-4327-4. Epub 2016 Oct 1.

Study record dates

Study Major Dates

• Study Start (Actual): January 9, 2023
• Primary Completion (Anticipated): February 1, 2024
• Study Completion (Anticipated): February 1, 2024

Study Registration Dates

• First Submitted: October 13, 2022
• First Submitted That Met QC Criteria: October 19, 2022
• First Posted (Actual): October 24, 2022

Study Record Updates

• Last Update Posted (Actual): May 9, 2023
• Last Update Submitted That Met QC Criteria: May 7, 2023
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Keywords: breastfeeding; hyaluronic acid; cracked nipple
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Immunologic Factors; Protective Agents; Adjuvants, Immunologic; Viscosupplements; Hyaluronic Acid
• Other Study ID Numbers: 123456 (UMMashhad)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No